Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Ligand Binding Sites

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Drug Delivery Strategy Exploiting Amino Acid Prodrugs: Improving Oral Bioavailability and Overcoming Nonlinear Pharmacokinetic Challenges Following Dose Escalation of a CK2 Inhibitor with Poor Solubility.

Journal of medicinal chemistry·2026

Same author

Discovery of BMS-159, an Orally Active Imidazotriazine Pan-CK2 Inhibitor for the Treatment of Cancer.

ACS medicinal chemistry letters·2026

Same author

DNA-Encoded Library (DEL) Selection Identifies a Distinct DDB1 Ligand Binding Site.

ACS medicinal chemistry letters·2026

Same author

Enhancing the Oral Bioavailability of a Poorly Soluble Pan-CK2 Kinase Inhibitor: Leveraging a Phosphate Prodrug Strategy to Overcome Dissolution-Limited Absorption and Improve Systemic Exposure during Dose Escalation.

Journal of medicinal chemistry·2026

Same author

Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models".

Journal of medicinal chemistry·2025

Same author

Multilayer SiO<sub></sub> derived from Si-Ca alloy <i>via</i> Fe<sub>2</sub>O<sub>3</sub> oxidization for Li-ion batteries.

Dalton transactions (Cambridge, England : 2003)·2025

Search research articles

Related Experiment Video

Updated: Oct 23, 2025

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

Evaluating Ligands for Ubiquitin Ligases Using Affinity Beads.

Jennifer Dobrodziej¹, Hanqing Dong¹, Kurt Zimmermann¹

¹Arvinas, Inc., New Haven, CT, USA.

Methods in Molecular Biology (Clifton, N.J.)

|August 25, 2021

Summary

Proteolysis-targeting chimera (PROTAC) protein degraders harness ubiquitin ligase enzymes (E3s) to eliminate disease-causing proteins. This study presents a method using E3 affinity beads to develop novel ligands for diverse E3 ligases, advancing degrader technology.

Keywords:

Biotin Degrader PROTAC Proteolysis Streptavidin Ubiquitin

More Related Videos

In Vitro Analysis of E3 Ubiquitin Ligase Function

In Vitro Analysis of E3 Ubiquitin Ligase Function

Published on: May 14, 2021

Functional Characterization of RING-Type E3 Ubiquitin Ligases In Vitro and In Planta

Functional Characterization of RING-Type E3 Ubiquitin Ligases In Vitro and In Planta

Published on: December 5, 2019

Related Experiment Videos

Last Updated: Oct 23, 2025

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

In Vitro Analysis of E3 Ubiquitin Ligase Function

In Vitro Analysis of E3 Ubiquitin Ligase Function

Published on: May 14, 2021

Functional Characterization of RING-Type E3 Ubiquitin Ligases In Vitro and In Planta

Functional Characterization of RING-Type E3 Ubiquitin Ligases In Vitro and In Planta

Published on: December 5, 2019

Area of Science:

Biochemistry
Molecular Biology
Drug Discovery

Background:

Proteolysis-targeting chimera (PROTAC) technology utilizes heterobifunctional molecules to induce targeted protein degradation via the ubiquitin-proteasome system.
While numerous ubiquitin ligase enzymes (E3s) exist, only a limited number are currently employed in PROTAC development, highlighting a need for broader E3 ligase utilization.
A significant hurdle in expanding PROTAC applications is the identification and development of high-quality ligands for underutilized E3 ligases.

Purpose of the Study:

To describe a novel method for developing ligands targeting various ubiquitin ligase enzymes (E3s) for protein degrader technology.
To facilitate the discovery of new PROTACs by enabling the use of a wider range of E3 ligases.
To provide a robust approach for evaluating ligand-protein interactions and functionality in a cell-free context.

Main Methods:

Development of E3 affinity beads through the conjugation of potential E3 ligands to biotin.
Utilizing the high-affinity interaction between biotin and streptavidin agarose for bead preparation.
Evaluation of ligand-protein interactions and functionality using cell or tissue extracts.

Main Results:

Successfully created E3 affinity beads by conjugating ligands to biotin-streptavidin agarose.
Demonstrated the utility of these beads for assessing ligand binding and functionality with E3 ligases.
Established a method for screening and validating ligands for diverse E3 ligases.

Conclusions:

E3 affinity beads offer a versatile platform for identifying and validating ligands for a broad spectrum of ubiquitin ligase enzymes.
This approach can accelerate the development of novel proteolysis-targeting chimera (PROTAC) protein degraders by expanding the repertoire of usable E3 ligases.
The described method provides a valuable tool for advancing targeted protein degradation therapeutics.